This information is intended only  for healthcare professionals resident in the United Kingdom

Prescribing Information (PI) for COMIRNATY® (tozinameran) COVID-19 mRNA Vaccine (nucleoside modified) Great Britain (GB) and Northern Ireland (NI)

Pfizer Ltd. accepts no responsibility for the content or services of the linked site other than the information relating to Pfizer medicines which it has provided or reviewed

Great Britain

  • COMIRNATY (tozinameran) 30 micrograms/dose concentrate for dispersion for injection 12+ years COVID-19 mRNA Vaccine (nucleoside modified) - PI for GB
  • COMIRNATY (tozinameran) 10 micrograms/dose concentrate for dispersion for injection Children 5 to 11 years COVID-19 mRNA Vaccine (nucleoside modified) - PI for GB

Northern Ireland

  • COMIRNATY (tozinameran) 30 micrograms/dose concentrate for dispersion for injection 12+ years COVID-19 mRNA Vaccine (nucleoside modified) - PI for NI
  • COMIRNATY (tozinameran) 10 micrograms/dose concentrate for dispersion for injection Children 5 to 11 years COVID-19 mRNA Vaccine (nucleoside modified) - PI for NI

COMIRNATY (tozinameran) 30 micrograms/dose concentrate for dispersion for injection 12+ years COVID-19 mRNA Vaccine (nucleoside modified) - PI for GB

COMIRNATY (tozinameran) 10 micrograms/dose concentrate for dispersion for injection Children 5 to 11 years COVID-19 mRNA Vaccine (nucleoside modified) - PI for GB

COMIRNATY (tozinameran) 30 micrograms/dose concentrate for dispersion for injection 12+ years COVID-19 mRNA Vaccine (nucleoside modified) - PI for NI

COMIRNATY (tozinameran) 10 micrograms/dose concentrate for dispersion for injection Children 5 to 11 years COVID-19 mRNA Vaccine (nucleoside modified) - PI for NI

PP-CMR-GBR-0237 March 2022